Streamlining I-O Therapeutic Antibody Discovery: An Interview with Tracey Mullen, COO of Abveris

By Ryan Kelly - December 03, 2019

Insights from industry: Tracey Mullen, Chief Operating Officer of Abveris

Visit News Medical today to view an interview with Tracey Mullen, Chief Operating Officer of Abveris, in the "Insights from Industry" interview series.

In the interview, Tracey gives an overview of immuno-oncology therapeutic antibodies in development, strategies for therapeutic antibody discovery, and applications for the Intellicyt iQue high-throughput flow cytometry platform in antibody discovery.

For more information on antibody discovery projects utilizing high-throughput flow cytometry, contact Abveris today!

VIEW THE INTERVIEW

intellicyt

HIGH-THROUGHPUT FLOW CYTOMETRY

Discover Antibodies to Cell Surface Targets

Abveris utilizes the Intellicyt iQue screener to streamline high-throughput flow cytometry for antibody discovery. With high-throughput flow cytometry, we maximize the chances of identifying diverse, functional antibodies for development as high-quality antibody therapeutics and interesting immuno-reagents. 

OUR TECHNOLOGY
Comments

We promise that we won't SPAM you.